explore -WSS

explore

author：Wikipedia 2025-10-01 14:59:21 - browse：7

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Wegovy trial has doctors encouraged over new possibilities

Wikipedia

WSS

How the political right came to back psychedelics to treat trauma

Petition to FDA: Get the lead out of consumer hair dyes

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

The best solution to the drug shortages problem

How to use technology to prevent future drug shortages

Study: Pain burden is higher in Black NFL players than white ones

Wikipedia

explore

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Peter Hotez and the public health issue of online harassment

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Dobbs anniversary: the lost opportunity of abortion as health care

New research casts further doubt on a common procedure used with IVF

What does generative AI mean for health care? We asked experts

Why failed clinical trials don’t always spell doom for a new drug

Apple is now the first public company to be valued at $3 trillion

Police still searching for prisoner who escaped from NYC hospital

hotspot

Oak trusses raised to roof of fire

Bulgari apologizes to China for listing Taiwan as a country after online backlash

New research casts further doubt on a common procedure used with IVF

Lecanemab for Alzheimer's is coming. Is the health system ready?

Anavex keeps shifting the goalposts in its clinical trials

A biotech analyst on neuroscience, placebo effect, not over

knowledge

Wikipedia

leisure time

entertainment